| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18435 R78134 |
Lee (Controls exposed to TCAs), 2025 | Admission to neonatal intensive care unit (NICU) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) |
0.40 [0.05;3.04] C excluded (control group) |
1/71 21/613 | 22 | 71 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18414 R77829 |
Lee (Controls unexposed, general pop), 2025 | Admission to neonatal intensive care unit (NICU) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 0.48 [0.07;3.45] | 1/71 8,566/463,440 | 8,567 | 71 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18262 R76713 |
Cornet, 2024 | Delayed neonatal adaptation (presence of at least one of the following: 5min Apgar score ≤5; positive pressure ventilation or intubation during delivery room resuscitation; or admission to the NICU with respiratory distress requiring invasive or non-invasive ventilation) | late pregnancy | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) | 3.86 [3.01;4.95] | -/382 12,078/272,517 | - | 382 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13122 R50020 |
Marks (Controls exposed to Bupropion), 2021 | Neonatal intensive care unit admission | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 1.68 [1.21;2.33] | 172/581 91/406 | 263 | 581 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6190 R16315 |
Klieger-Grossmann, 2012 | Neonatal intensive care unit admission | late pregnancy | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 1.32 [0.59;2.94] C | 14/172 12/191 | 26 | 172 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 1.88 [0.95;3.72] | 8,856 | 1,206 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, general pop; 2: Controls exposed to Bupropion;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 18435